Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Solomon, Benjamin J.
Gettinger, Scott N.
Riely, Gregory J.
Gadgeel, Shirish M.
Nokihara, Hiroshi
Han, Ji-Youn
Hida, Toyoaki
Satouchi, Miyako
Baldini, Editta
Siena, Salvatore
Yamamoto, Nobuyuki
Horn, Leora
Tassell, Vanessa Roberts
Polli, Anna
Camidge, D. Ross
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Yale Univ, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan
[6] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[9] Campo di Marte Hosp, Lucca, Italy
[10] Azienda Osped Niguarda Ca Granda, Milan, Italy
[11] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan
[12] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[13] Pfizer Oncol, La Jolla, CA USA
[14] Pfizer Italia Srl, Milan, Italy
[15] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8105
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CRIZOTINIB VERSUS PEMETREXED OR DOCETAXEL CHEMOTHERAPY IN ADVANCED, ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A RANDOMIZED PHASE III STUDY (PROFILE 1007)
    Kim, Dong-wan
    Janne, Pasi A.
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, I.
    Ahn, Myung-ju
    De Pas, T. M.
    Besse, Benjamin
    Solomon, Ben
    Blackball, Fiona
    Wu, Yi-long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. R.
    Hirsh, Vera
    Mok, Tony S. K.
    Tassell, Vanessa
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S445 - S446
  • [2] CRIZOTINIB VS. PEMETREXED OR DOCETAXEL IN ADVANCED ALK plus NON-SMALL CELL LUNG CANCER: SUBGROUP ANALYSIS IN PROFILE 1007
    Yamamoto, N.
    Nokihara, H.
    Han, J. -Y.
    Hida, T.
    Riely, G. J.
    Baldini, E.
    Salvatore, S.
    Horn, L.
    Polli, A.
    Satouchi, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [3] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [6] A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Scagliotti, Giorgio
    Kim, Dong-Wan
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Riely, Gregory J.
    Gettinger, Scott N.
    Besse, Benjamin
    Thomas, Michael
    Salgia, Ravi
    Wilner, Keith D.
    Bartlett, Cynthia Huang
    Polli, Anna
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Kim, D.
    Ahn, M.
    Yang, P.
    Liu, X.
    De Pas, T.
    Crino, L.
    Lanzalone, S.
    Polli, A.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 402 - 402
  • [8] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [9] A LARGE RETROSPECTIVE ANALYSIS OF PEMETREXED (PEM) ACTIVITY IN PATIENTS (PTS) WITH ALK-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) PRIOR TO CRIZOTINIB (CRIZ) TREATMENT
    Scagliotti, G.
    Kim, D. W.
    Shaw, A. T.
    Ou, S. I.
    Riely, G. J.
    Gettinger, S.
    Besse, B.
    Wilner, K.
    Tang, Y.
    Bartlett, C. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 415 - 415
  • [10] First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Solomon, Benjamin J.
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Tursi, Jennifer
    Blackhall, Fiona Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345